Denufosol, formerly known as INS-37217, a P2Y2 agonist potentially for the treatment of cystic fibrosis. Cystic fibrosis is characterised by a defect of the chloride channel CFTR (cystic fibrosis transmembrane conductance regulator) on epithelial cells in the lungs. The CFTR regulates the components of sweat, digestive juices, and mucus. Defects lead to a viscous, dehydrated mucus, hindering mucociliary clearance. Denufosol is an agonist at the P2Y2 subtype of purinergic receptors, an alternative chloride channel. Activating this alternate chloride channel theoretically increases ion transport in cystic fibrosis patients which compensates the effects caused by the non-functioning CFTR. References: Moss RB. Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis. J Pediatr. 2013 Apr;162(4):676-80. doi: 10.1016/j.jpeds.2012.11.034. Epub 2013 Jan 3. PubMed PMID: 23290508.

纯度：≥98%

CAS：318250-11-2